http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 29 Aug 2024 06:14:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html <p>GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p><p>In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have an exercise price of $5.00 http://www.streetinsider.com/Equity+Offerings/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html Thu, 29 Aug 2024 06:14:07 -0400 GOVX GOVXW http://www.streetinsider.com/Equity+Offerings/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html <p>GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p><p>In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have an exercise price of $5.00 http://www.streetinsider.com/Equity+Offerings/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html Thu, 29 Aug 2024 06:14:07 -0400 GOVX GOVXW http://www.streetinsider.com/Corporate+News/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html <p>GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p><p>In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have an exercise price of $5.00 http://www.streetinsider.com/Corporate+News/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html Thu, 29 Aug 2024 06:14:07 -0400 GOVX GOVXW http://www.streetinsider.com/Corporate+News/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html <p>GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p><p>In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have an exercise price of $5.00 http://www.streetinsider.com/Corporate+News/Geovax+Labs+Inc.+%28GOVX%29+Prices+975.61K+Share+Offering+at+%245.125sh/23661307.html Thu, 29 Aug 2024 06:14:07 -0400 GOVX GOVXW http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Press+Releases/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html <p>ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.</p> <p>In addition, in a concurrent private placement, the Company will issue to the investor warrants http://www.streetinsider.com/Globe+Newswire/GeoVax+to+Raise+Approximately+%245.0+Million+of+Gross+Proceeds+in+Offering+Priced+At-the-Market/23660327.html Wed, 28 Aug 2024 20:59:00 -0400 A.01857600 GOVX GOVXW O.00080482 O.00642569 http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Press+Releases/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html <p align="center"><em>Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention</em></p> <p>ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (Nasdaq: GOVX) (&quot;GeoVax Labs&quot; or the &quot;Company&quot;), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&amp;A Event titled &quot;Now Is Not the Time to Monkey(pox) Around.&quot;  The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August http://www.streetinsider.com/Globe+Newswire/Registration+is+Now+Open+for+Tribe+Public%E2%80%99s+Webinar+Event+%26quot%3BNow+Is+Not+the+Time+to+Monkey%28pox%29+Around%26quot%3B+Featuring+GeoVax+Lab%E2%80%99s+CEO/23627446.html Wed, 21 Aug 2024 09:00:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html <p align="start"><i>Company plans Phase 2 trial in first-recurrence head &amp; neck cancer,</i> <i>in combination with immune checkpoint inhibitor</i><br/></p> <p align="start">ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review.</p> <p align="start">GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html Wed, 31 Jul 2024 10:15:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html <p align="start"><i>Company plans Phase 2 trial in first-recurrence head &amp; neck cancer,</i> <i>in combination with immune checkpoint inhibitor</i><br/></p> <p align="start">ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review.</p> <p align="start">GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html Wed, 31 Jul 2024 10:15:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html <p align="start"><i>Company plans Phase 2 trial in first-recurrence head &amp; neck cancer,</i> <i>in combination with immune checkpoint inhibitor</i><br/></p> <p align="start">ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review.</p> <p align="start">GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 http://www.streetinsider.com/Press+Releases/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html Wed, 31 Jul 2024 10:15:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Globe+Newswire/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html <p align="start"><i>Company plans Phase 2 trial in first-recurrence head &amp; neck cancer,</i> <i>in combination with immune checkpoint inhibitor</i><br/></p> <p align="start">ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review.</p> <p align="start">GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 http://www.streetinsider.com/Globe+Newswire/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html Wed, 31 Jul 2024 10:15:00 -0400 GOVX GOVXW O.00642569 http://www.streetinsider.com/Globe+Newswire/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html <p align="start"><i>Company plans Phase 2 trial in first-recurrence head &amp; neck cancer,</i> <i>in combination with immune checkpoint inhibitor</i><br/></p> <p align="start">ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review.</p> <p align="start">GeoVax and a specially convened clinical advisory committee have completed a comprehensive review of the recently completed PNP-002 Phase 1b/2a trial, together with the previously completed PNP-001 Phase 1 http://www.streetinsider.com/Globe+Newswire/Update%3A%C2%A0GeoVax+Announces+Phase+2+Plans+for%C2%A0Gedeptin%C2%AE%C2%A0Cancer+Therapy+Following+Clinical+Advisory+Committee+Review/23529969.html Wed, 31 Jul 2024 10:15:00 -0400 GOVX GOVXW O.00642569